Table 2.

Factors associated with seroprevalence, test-retest positivity, and incidence of IgM or IgG anti-SARS-CoV-2 antibodies at the 1-month follow-up

	Seroprevalence	Test-retest positivity	Incidence
Age, years
<12	ref	ref	ref
12–17	1·07 (0·94–1·22)	1·00 (0·83–1·21)	1·20 (0·22–6·40)
18–29	0·85 (0·73–0·98)*	0·71 (0·58–0·88)†	0·75 (0·14–4·01)
30–59	0·97 (0·87–1·08)	1·01 (0·88–1·16)	0·60 (0·14–2·63)
≥60	0·99 (0·84–1·18)	1·09 (0·90–1·31)	0·82 (0·09–7·16)
Area of residence
Rural	ref	ref	ref
Urban	1·01 (0·77–1·09)	0·92 (0·77–1·09)	0·21 (0·07–0·68)†
Sex
Female	ref	ref	ref
Male	0·97 (0·88–1·05)	0·98 (0·87–1·09)	1·12 (0·36–3·44)
District
Belen	ref	ref	ref
Iquitos	0·94 (0·84–1·07)	1·19 (0·98–1·44)	0·47 (0·10–2·30)
Punchana	0·93 (0·81–1·07)	1·15 (0·93–1·42)	0·32 (0·03–3·01)
San Juan	0·91 (0·80–1·03)	1·15 (0·95–1·36)	0·82 (0·20–3·35)

Data are prevalence ratio (95% CI).

^*p<0·05.

^†p<0·01.